These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 23765529)

  • 21. EGFR Mutation status in Japanese lung cancer patients: genotyping analysis using LightCycler.
    Sasaki H; Endo K; Konishi A; Takada M; Kawahara M; Iuchi K; Matsumura A; Okumura M; Tanaka H; Kawaguchi T; Shimizu T; Takeuchi H; Yano M; Fukai I; Fujii Y
    Clin Cancer Res; 2005 Apr; 11(8):2924-9. PubMed ID: 15837743
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Direct comparison of 3 PCR methods in detecting EGFR mutations in patients with advanced non-small-cell lung cancer.
    Ikeda T; Nakamura Y; Yamaguchi H; Tomonaga N; Doi S; Nakatomi K; Iida T; Motoshima K; Mizoguchi K; Nagayasu T; Tsukamoto K; Kohno S
    Clin Lung Cancer; 2012 Sep; 13(5):369-74. PubMed ID: 22410386
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib.
    Riely GJ; Pao W; Pham D; Li AR; Rizvi N; Venkatraman ES; Zakowski MF; Kris MG; Ladanyi M; Miller VA
    Clin Cancer Res; 2006 Feb; 12(3 Pt 1):839-44. PubMed ID: 16467097
    [TBL] [Abstract][Full Text] [Related]  

  • 24. EGFR mutation status in tumour-derived DNA from pleural effusion fluid is a practical basis for predicting the response to gefitinib.
    Kimura H; Fujiwara Y; Sone T; Kunitoh H; Tamura T; Kasahara K; Nishio K
    Br J Cancer; 2006 Nov; 95(10):1390-5. PubMed ID: 17060940
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Screening for EGFR mutations in lung cancer by a novel real-time PCR with double-loop probe and Sanger DNA sequencing].
    Zhang HP; Ruan L; Zheng LM; Bai DY; Zhang HF; Liao YQ; Ding Y
    Zhonghua Zhong Liu Za Zhi; 2013 Jan; 35(1):28-32. PubMed ID: 23648296
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficiency of the Therascreen® RGQ PCR kit for the detection of EGFR mutations in non-small cell lung carcinomas.
    Vallée A; Le Loupp AG; Denis MG
    Clin Chim Acta; 2014 Feb; 429():8-11. PubMed ID: 24269715
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A novel, rapid point-of-care test for lung cancer patients to detect epidermal growth factor receptor gene mutations by using real-time droplet-PCR and fresh liquid cytology specimens.
    Asaka S; Yoshizawa A; Matsuda K; Yamaguchi A; Yamamoto H; Shiina T; Nakata R; Ogawa K; Zhang M; Honda T
    Oncol Rep; 2017 Feb; 37(2):1020-1026. PubMed ID: 27922678
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Performance evaluation comparison of 3 commercially available PCR-based KRAS mutation testing platforms.
    Adams JA; Post KM; Bilbo SA; Wang X; Sen JD; Cornwell AJ; Malek AJ; Cheng L
    Appl Immunohistochem Mol Morphol; 2014 Mar; 22(3):231-5. PubMed ID: 24614151
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rapid detection of epidermal growth factor receptor mutations in lung cancer by the SMart-Amplification Process.
    Hoshi K; Takakura H; Mitani Y; Tatsumi K; Momiyama N; Ichikawa Y; Togo S; Miyagi T; Kawai Y; Kogo Y; Kikuchi T; Kato C; Arakawa T; Uno S; Cizdziel PE; Lezhava A; Ogawa N; Hayashizaki Y; Shimada H
    Clin Cancer Res; 2007 Sep; 13(17):4974-83. PubMed ID: 17785547
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mutations of epidermal growth factor receptor of non-small cell lung cancer were associated with sensitivity to gefitinib in recurrence after surgery.
    Kondo M; Yokoyama T; Fukui T; Yoshioka H; Yokoi K; Nagasaka T; Imaizumi K; Kume H; Hasegawa Y; Shimokata K; Sekido Y
    Lung Cancer; 2005 Dec; 50(3):385-91. PubMed ID: 16140420
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Epidermal growth factor receptor gene mutation in non-small cell lung cancer using highly sensitive and fast TaqMan PCR assay.
    Endo K; Konishi A; Sasaki H; Takada M; Tanaka H; Okumura M; Kawahara M; Sugiura H; Kuwabara Y; Fukai I; Matsumura A; Yano M; Kobayashi Y; Mizuno K; Haneda H; Suzuki E; Iuchi K; Fujii Y
    Lung Cancer; 2005 Dec; 50(3):375-84. PubMed ID: 16199108
    [TBL] [Abstract][Full Text] [Related]  

  • 32. EGFR mutation detection by microfluidic technology: a validation study.
    Malapelle U; Russo S; Pepe F; Sgariglia R; De Luca C; Bellevicine C; Pallante P; Troncone G
    J Clin Pathol; 2013 Nov; 66(11):982-4. PubMed ID: 23794480
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification of non-small-cell lung cancer with activating EGFR mutations in malignant effusion and cerebrospinal fluid: rapid and sensitive detection of exon 19 deletion E746-A750 and exon 21 L858R mutation by immunocytochemistry.
    Kawahara A; Azuma K; Sumi A; Taira T; Nakashima K; Aikawa E; Abe H; Yamaguchi T; Takamori S; Akiba J; Kage M
    Lung Cancer; 2011 Oct; 74(1):35-40. PubMed ID: 21444121
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan.
    Huang SF; Liu HP; Li LH; Ku YC; Fu YN; Tsai HY; Chen YT; Lin YF; Chang WC; Kuo HP; Wu YC; Chen YR; Tsai SF
    Clin Cancer Res; 2004 Dec; 10(24):8195-203. PubMed ID: 15623594
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials.
    Bell DW; Lynch TJ; Haserlat SM; Harris PL; Okimoto RA; Brannigan BW; Sgroi DC; Muir B; Riemenschneider MJ; Iacona RB; Krebs AD; Johnson DH; Giaccone G; Herbst RS; Manegold C; Fukuoka M; Kris MG; Baselga J; Ochs JS; Haber DA
    J Clin Oncol; 2005 Nov; 23(31):8081-92. PubMed ID: 16204011
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinicopathologic significance of the mutations of the epidermal growth factor receptor gene in patients with non-small cell lung cancer.
    Tomizawa Y; Iijima H; Sunaga N; Sato K; Takise A; Otani Y; Tanaka S; Suga T; Saito R; Ishizuka T; Dobashi K; Minna JD; Nakajima T; Mori M
    Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6816-22. PubMed ID: 16203769
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Epidermal growth factor receptor mutations in 510 Finnish non--small-cell lung cancer patients.
    Mäki-Nevala S; Rönty M; Morel M; Gomez M; Dawson Z; Sarhadi VK; Telaranta-Keerie A; Knuuttila A; Knuutila S
    J Thorac Oncol; 2014 Jun; 9(6):886-91. PubMed ID: 24828666
    [TBL] [Abstract][Full Text] [Related]  

  • 38. therascreen® EGFR RGQ PCR Kit: A Companion Diagnostic for Afatinib and Gefitinib in Non-Small Cell Lung Cancer.
    Syed YY
    Mol Diagn Ther; 2016 Apr; 20(2):191-8. PubMed ID: 26891729
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Abnormalities of epidermal growth factor receptor in lung squamous-cell carcinomas, adenosquamous carcinomas, and large-cell carcinomas: tyrosine kinase domain mutations are not rare in tumors with an adenocarcinoma component.
    Ohtsuka K; Ohnishi H; Fujiwara M; Kishino T; Matsushima S; Furuyashiki G; Takei H; Koshiishi Y; Goya T; Watanabe T
    Cancer; 2007 Feb; 109(4):741-50. PubMed ID: 17238183
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer.
    Chou TY; Chiu CH; Li LH; Hsiao CY; Tzen CY; Chang KT; Chen YM; Perng RP; Tsai SF; Tsai CM
    Clin Cancer Res; 2005 May; 11(10):3750-7. PubMed ID: 15897572
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.